Actinium Pharmaceuticals, Inc. (ATNM)
1.57
+0.19
(+13.77%)
USD |
NYAM |
Oct 22, 15:29
Actinium Pharmaceuticals Enterprise Value : 8.257M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 8.257M |
| October 20, 2026 | 8.886M |
| October 19, 2026 | 6.371M |
| October 16, 2026 | 0.3968M |
| October 15, 2026 | -1.804M |
| October 14, 2026 | -4.489M |
| October 13, 2026 | -3.706M |
| October 12, 2026 | -1.804M |
| October 09, 2026 | -0.5465M |
| October 08, 2026 | -1.175M |
| October 07, 2026 | -1.490M |
| October 06, 2026 | -0.232M |
| October 05, 2026 | 2.598M |
| October 02, 2026 | 1.654M |
| October 01, 2026 | 1.026M |
| September 30, 2026 | 0.0824M |
| September 29, 2026 | 0.7112M |
| September 28, 2026 | 1.969M |
| September 25, 2026 | 2.598M |
| September 24, 2026 | 2.283M |
| September 23, 2026 | 1.969M |
| September 22, 2026 | 1.654M |
| September 21, 2026 | 2.598M |
| September 18, 2026 | 3.226M |
| September 17, 2026 | 2.283M |
| Date | Value |
|---|---|
| September 16, 2026 | 3.855M |
| September 15, 2026 | 4.170M |
| September 14, 2026 | 5.113M |
| September 11, 2026 | 8.886M |
| September 10, 2026 | 6.056M |
| September 09, 2026 | 3.541M |
| September 08, 2026 | 3.541M |
| September 04, 2026 | -2.747M |
| September 03, 2026 | -2.118M |
| September 02, 2026 | -3.691M |
| September 01, 2026 | -3.832M |
| August 31, 2026 | -3.062M |
| August 28, 2026 | -3.376M |
| August 27, 2026 | -3.691M |
| August 26, 2026 | -3.376M |
| August 25, 2026 | -1.175M |
| August 24, 2026 | -2.118M |
| August 21, 2026 | -0.5465M |
| August 20, 2026 | 0.0824M |
| August 19, 2026 | 0.3968M |
| August 18, 2026 | -1.175M |
| August 17, 2026 | -2.118M |
| August 14, 2026 | -2.433M |
| August 13, 2026 | -4.826M |
| August 12, 2026 | -9.316M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.593B |
| Alnylam Pharmaceuticals, Inc. | 29.78B |
| Anika Therapeutics, Inc. | 262.53M |
| Savara, Inc. | 816.59M |
| Vericel Corp. | 2.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 27.90M |
| Revenue (Quarterly) | 35.00M |
| Total Expenses (Quarterly) | 7.099M |
| EPS Diluted (Quarterly) | 0.8884 |
| Gross Profit Margin (Quarterly) | 98.77% |
| Profit Margin (Quarterly) | 79.72% |
| Earnings Yield | 22.72% |
| Operating Earnings Yield | 19.47% |
| Normalized Earnings Yield | 22.72 |